How much funding has TRexBio raised?

TRexBio has raised $219.0M in total funding, most recently a Extension Round.

Who are TRexBio's investors?

TRexBio's investors include Delos Capital, Polaris Partners, SV Health Investors, Pfizer Ventures, Johnson & Johnson Innovation, Alexandria Venture Investments.

Where is TRexBio headquartered?

TRexBio is headquartered in South San Francisco, United States.

What industry is TRexBio in?

TRexBio operates in Biotech, Healthcare.

TRexBio

TRex Bio

South San Francisco, United States · Founded 2018 · $219.0M raised

Biotech

Healthcare

Headquarters: South San Francisco
Employees: 11–50
Founded: 2018
Business Model: B2B

Website: trex.bio
Total Funding: $219.0M
Last Round: $50.0M Extension RoundJan 2026
Rounds: 4

About

TRexBio is a South San Francisco-based clinical-stage biotechnology company developing purpose-built biologics that restore immune balance in autoimmune and inflammatory diseases. Founded in 2018 with seed funding from SV Health Investors, TRexBio's platform leverages deep tissue biology to design biologics capable of selectively modulating immune responses. The company raised M in a Series B extension in January 2026 to advance its pipeline including programs for atopic dermatitis.

Summary

TRexBio is a Biotech company based in South San Francisco, United States, founded in 2018. It has raised $219.0M in total across 4 rounds, most recently a $50.0M Extension Round round in Jan 2026. Investors include Delos Capital, Polaris Partners and SV Health Investors.